Pathology and Classification of Gliomas

2015 ◽  
pp. 1-84 ◽  
Author(s):  
K. J. Z�lch ◽  
W. Wechsler
Author(s):  
Keisuke Miyake ◽  
Kenta Suzuki ◽  
Tomoya B Ogawa ◽  
Daisuke Ogawa ◽  
Tetsuhiro Hatakeyama ◽  
...  

Abstract Background The molecular diagnosis of gliomas such as isocitrate dehydrogenase (IDH) status (wild-type [wt] or mutation [mut]) is especially important in the 2016 WHO classification. Positron emission tomography (PET) has afforded molecular and metabolic diagnostic imaging. The present study aimed to define the interrelationship between the 2016 WHO classification of gliomas and the integrated data from PET images using multiple tracers, including 18F-fluorodeoxyglucose ( 18F-FDG), 11C-methionine ( 11C-MET), 18F-fluorothymidine ( 18F-FLT), and 18F-fluoromisonidazole ( 18F-FMISO). Methods This retrospective, single-center study comprised 113 patients with newly diagnosed glioma based on the 2016 WHO criteria. Patients were divided into four glioma subtypes (Mut, Codel, Wt, and glioblastoma multiforme [GBM]). Tumor standardized uptake value (SUV) divided by mean normal cortical SUV (tumor-normal tissue ratio [TNR]) was calculated for 18F-FDG, 11C-MET, and 18F-FLT. Tumor-blood SUV ratio (TBR) was calculated for 18F-FMISO. To assess the diagnostic accuracy of PET tracers in distinguishing glioma subtypes, a comparative analysis of TNRs and TBR as well as the metabolic tumor volume (MTV) were calculated by Scheffe’s multiple comparison procedure for each PET tracer following the Kruskal–Wallis test. Results The differences in mean 18F-FLT TNR and 18F-FMISO TBR were significant between GBM and other glioma subtypes (p < 0.001). Regarding the comparison between Gd-T1WI volumes and 18F-FLT MTVs or 18F-FMISO MTVs, we identified significant differences between Wt and Mut or Codel (p < 0.01). Conclusion Combined administration of four PET tracers might aid in the preoperative differential diagnosis of gliomas according to the 2016 WHO criteria.


2018 ◽  
Vol 44 (2) ◽  
pp. 139-150 ◽  
Author(s):  
P. Wesseling ◽  
D. Capper

1989 ◽  
Vol 12 (3) ◽  
pp. 233-238 ◽  
Author(s):  
Ulrich Szuwart ◽  
Harald Bennefeld ◽  
Hildegund Behr

2018 ◽  
Vol 20 (suppl_5) ◽  
pp. v346-v346
Author(s):  
Laurent James Livermore ◽  
Martin Isabelle ◽  
Ian Bell ◽  
Puneet Plaha ◽  
Claire Vallance ◽  
...  

Cancers ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1622 ◽  
Author(s):  
Ricardo Gargini ◽  
Berta Segura-Collar ◽  
Pilar Sánchez-Gómez

Brain tumors encompass a diverse group of neoplasias arising from different cell lineages. Tumors of glial origin have been the subject of intense research because of their rapid and fatal progression. From a clinical point of view, complete surgical resection of gliomas is highly difficult. Moreover, the remaining tumor cells are resistant to traditional therapies such as radio- or chemotherapy and tumors always recur. Here we have revised the new genetic and epigenetic classification of gliomas and the description of the different transcriptional subtypes. In order to understand the progression of the different gliomas we have focused on the interaction of the plastic tumor cells with their vasculature-rich microenvironment and with their distinct immune system. We believe that a comprehensive characterization of the glioma microenvironment will shed some light into why these tumors behave differently from other cancers. Furthermore, a novel classification of gliomas that could integrate the genetic background and the cellular ecosystems could have profound implications in the efficiency of current therapies as well as in the development of new treatments.


2016 ◽  
Vol 35 (01) ◽  
pp. 31-37 ◽  
Author(s):  
Kimberly J. Johnson ◽  
Michael E. Scheurer ◽  
Adelheid Woehrer ◽  
Joseph Wiemels

1995 ◽  
Vol 2 (3) ◽  
pp. 175-180 ◽  
Author(s):  
Paul D. Lewis

Sign in / Sign up

Export Citation Format

Share Document